{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:55:02Z","timestamp":1777859702867,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Medical management for type B aortic dissections (TBADs) require aggressive blood pressure and heart rate control to minimize further dissection extension and to restore perfusion to vital organs. Current guidelines recommend \u03b2-blockers (BB) as first-line therapy, however do not differentiate an ideal agent for use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study evaluated the hemodynamic safety of continuous infusion labetalol compared to esmolol combination (EC) therapies for TBADs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This single-center, retrospective analysis identified patients with a TBAD who received high dose continuous intravenous labetalol (HD-CIVL) or EC therapies. Patients who received HD-CIVL or EC therapies for a minimum of 2 hours, during which a minimum of 4 blood-pressure readings were recorded, were included. The primary end point was the incidence of hemodynamic instability with the use of HD-CIVL versus EC therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 20 patients receiving HD-CIVL and 22 patients receiving EC therapy were included in the analysis. Ten (50%) of patients receiving HD-CIVL and 7 (32%) of patients receiving EC therapies met the clinical definition of hemodynamic instability ( P = .23). Patients experiencing hemodynamic instability were all due to hypotension, with one also being due to bradycardia. Over half the patients in both groups had discontinued therapy ( P = .06) and were administered bolus fluids ( P = .27). Only one patient receiving HD-CIVL required vasopressor administration while none in the EC group ( P = .48).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study suggests that HD-CIVL is associated with a nonstatistical significant higher incidence of hemodynamic instability compared to an EC regimen in TBADs. Further studies are warranted in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190020929807","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T06:38:31Z","timestamp":1592375911000},"page":"870-874","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Hemodynamic Safety of Continuous Infusion Labetalol Versus Esmolol Combination Therapies for Type B Aortic Dissections"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-0141","authenticated-orcid":false,"given":"Kayla L.","family":"Myers","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Leong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"issue":"13","key":"bibr1-0897190020929807","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1161\/CIR.0b013e3181d47d48","volume":"121","author":"Hiratzka LF","year":"2010","journal-title":"Circulation"},{"issue":"75","key":"bibr2-0897190020929807","first-page":"1","volume":"4","author":"Schepens MAA","year":"2018","journal-title":"J Vis Surg"},{"key":"bibr3-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000274"},{"issue":"4","key":"bibr4-0897190020929807","first-page":"413","volume":"3","author":"Suzuki T","year":"2014","journal-title":"Ann Cardiothorac Surg"},{"issue":"2","key":"bibr5-0897190020929807","first-page":"CD010426","author":"Chan KK","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr6-0897190020929807","unstructured":"Pevtsov A, Kerndt C, Fredlund KL. Stat Pearls Publishing; 2019. Accessed October 1, 2019. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30085507"},{"key":"bibr7-0897190020929807","unstructured":"Miller M, Maani C. Labetalol. Stat Pearls Publishing; 2018. Accessed October 1, 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534787\/"},{"issue":"4","key":"bibr8-0897190020929807","first-page":"288","volume":"5","author":"Angaran DM","year":"1986","journal-title":"Clin Pharm"},{"issue":"13","key":"bibr9-0897190020929807","first-page":"6","volume":"2","author":"Fahed S","year":"2008","journal-title":"Patient Saf Surg"},{"key":"bibr10-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002400303"},{"key":"bibr11-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxy045"},{"key":"bibr12-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.2.522b"},{"key":"bibr13-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.2.522b"},{"key":"bibr14-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(84)90838-X"},{"key":"bibr15-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.98"},{"key":"bibr16-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04719.x"},{"key":"bibr17-0897190020929807","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2006.00213.x"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020929807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190020929807","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020929807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:35:59Z","timestamp":1777509359000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190020929807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/0897190020929807"],"URL":"https:\/\/doi.org\/10.1177\/0897190020929807","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]}}}